Medication info
Neo tablets 160 mg (Valsartan)

Neo tablets 160 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Shinil Pharmaceutical Co., Ltd.
Appearance
An oval film-coated tablet with an orange color and grayish tint
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201602897 · Approved 2016.05.24 · Insurance code 653806240

Summary

Main use
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; improvement of heart failure
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose, regardless of sex or race, is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. The dose should then be increased over several weeks, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or higher. However, since there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more daily are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Shinil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; improvement of heart failure

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular contractile dysfunction
View approved original text

This medication is primarily used to manage essential hypertension. It is also effective for heart failure patients with ACE inhibitor intolerance, helping to treat those with moderate to severe symptomatic heart failure. After myocardial infarction, it is used to reduce the risk of death in patients with left ventricular dysfunction or reduced contractility. Overall, it is used to improve patients' cardiovascular health by preventing complications associated with hypertension, heart failure, and myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose, regardless of sex or race, is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. The dose should then be increased over several weeks, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or higher. However, since there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine to these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If doses of 80 mg or more daily are administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Do not administer to individuals with allergies to this medication or its components, pregnant or potentially pregnant women, nursing mothers, patients with severe liver or kidney disorders. Special caution is required when administering to the elderly, patients with hyperkalemia, mild to moderate liver disorders, and those with heart disease; it is safer to start at a low dose and gradually increase the dosage. While taking this medication, side effects such as headache, dizziness, fatigue, cough, and diarrhea may occur, and in rare cases, serious adverse reactions such as angioedema, kidney damage, and hepatitis may also occur. This medication can lower blood pressure rapidly, so patients on dialysis or taking diuretics, and those on strict salt restrictions should be cautious about hypotension and consult healthcare professionals immediately if symptoms occur. Interactions may occur when taken with other blood pressure medications, diuretics, or potassium-sparing diuretics, so inform the healthcare provider of any other medications being taken. Use during pregnancy or nursing is discouraged; if unavoidable, nursing must be stopped. The safety and efficacy in children and adolescents under 18 years of age have not been established; therefore, use is not recommended. In the case of overdose, severe hypotension, decreased consciousness, and shock may occur, requiring immediate hospital treatment. This medication should be kept out of reach of children, and transferring it to another container may compromise its quality, which should be avoided. During treatment, regular monitoring of blood pressure, kidney function, and serum potassium levels is required, and any abnormal symptoms should be discussed with healthcare professionals immediately.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and it should be kept in a cool place below 30 degrees Celsius, away from direct sunlight and high temperatures. Storing it this way will help maintain the medication's effectiveness for a longer duration.

Appearance and packaging

Appearance

An oval film-coated tablet with an orange color and grayish tint

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.